Get the Stockscreener App
1.02
11.30%
-0.13
After Hours:
1.04
0.02
+1.96%
Invivyd Inc stock is traded at $1.02, with a volume of 328.26K.
It is down -11.30% in the last 24 hours and up +19.97% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.15
Open:
$1.17
24h Volume:
328.26K
Relative Volume:
0.53
Market Cap:
$121.23M
Revenue:
-
Net Income/Loss:
$-198.64M
P/E Ratio:
-0.6335
EPS:
-1.61
Net Cash Flow:
$-173.78M
1W Performance:
-15.00%
1M Performance:
+19.97%
6M Performance:
-77.03%
1Y Performance:
-40.00%
1-Day Range:
$0.9801
$1.18
1-Week Range:
$0.98
$1.19
52-Week Range:
$0.8116
$5.195
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Invivyd Inc: Rising -81.14% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Invivyd Inc [IVVD] Records 200-Day SMA of $2.5044 - Knox Daily
Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Take off with Invivyd Inc (IVVD): Get ready for trading - SETE News
Invivyd reports stable pemivibart potency against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com
Invivyd Inc (IVVD) is a good investment, but the stock may be undervalued - US Post News
Investor’s Toolkit: Key Ratios for Assessing Invivyd Inc (IVVD)’s Performance - The Dwinnex
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com India
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - ForexTV.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - GlobeNewswire
Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA - StreetInsider.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated - Daily Guardian Canada
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - StockTitan
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Global BMI Index - Marketscreener.com
Acadian Asset Management LLC Acquires 474,301 Shares of Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Invivyd Inc (IVVD)’s highs and lows: A closer look at its stock price fluctuations - US Post News
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate - Yahoo Finance
IVVD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
A company insider recently sold 112,381 shares of Invivyd Inc [IVVD]. Should You Sale? - Knox Daily
When Will Invivyd, Inc. (NASDAQ:IVVD) Breakeven? - Simply Wall St
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 - ForexTV.com
Enphase, First Solar, FedEx, Progyny, Steelcase, and More Stock Market Movers - Barron's
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Invivyd Inc [IVVD] stock for 186,575 USD was sold by MCGUIRE TERRANCE - Knox Daily
Invivyd to Participate in Upcoming Investor Conferences - Yahoo Finance UK
Invivyd begins Phase 1 trial for new COVID-19 antibody - Investing.com India
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ - ForexTV.com
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation ... - Post Register
Invivyd begins Phase 1 trial for new COVID-19 antibody - Investing.com
Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright - Defense World
Invivyd shares hold Buy as new data and updates bolster COVID-19 strategy - Investing.com
Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright - MarketBeat
Ratio Examination: Invivyd Inc (IVVD)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest - ForexTV.com
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest - StockTitan
Analytical Overview: Invivyd Inc (IVVD)’s Ratios Tell a Financial Story - The Dwinnex
Invivyd shares hold Buy rating with price target post-data By Investing.com - Investing.com Australia
Invivyd shares hold Buy rating with price target post-data - Investing.com India
Invivyd shares hold Buy rating with price target post-data - Investing.com
Recent Insider Activity Could Benefit Invivyd Inc (IVVD) - Knox Daily
Invivyd shares hold Buy rating with price target post-data By Investing.com - Investing.com Canada
Views of Wall Street’s Leading Experts on Invivyd Inc - SETE News
Invivyd’s (IVVD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Pemivibart shows promise in COVID-19 prevention trial By Investing.com - Investing.com Australia
Invivyd PrEPs for COVID-19 with Pemgarda data; season ‘upon us’ - BioWorld Online
Invivyd's (IVVD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Pemivibart shows promise in COVID-19 prevention trial - Investing.com
Invivyd Inc: Analyzing IVVD Stock Trends - The InvestChronicle
Pemivibart shows promise in COVID-19 prevention trial By Investing.com - Investing.com UK
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial - ForexTV.com
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):